Clinical trial
Gemcitabine With/Out Erlotinib in Unresectable Locally Advanced/Metastatic…
NCT00026338 · NCIC Clinical Trials Group, Other · Completed
Key facts
| NCT number | NCT00026338 |
|---|---|
| Title | Gemcitabine With/Out Erlotinib in Unresectable Locally Advanced/Metastatic Pancreatic Cancer |
| Official title | A Randomized Placebo Controlled Study Of OSI-774 (TARCEVA) Plus Gemcitabine In Patients With Locally Advanced, Unresectable Or Metastatic Pancreatic Cancer |
| Lead sponsor | NCIC Clinical Trials Group, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Drug |
| Interventions | erlotinib hydrochloride, gemcitabine hydrochloride |
| Enrollment | 569 |
| Start date | Oct 29, 2001 |
| Primary completion | Sep 17, 2004 |
| Completion | Feb 10, 2009 |
| First posted | Jan 27, 2003 |
| Last update posted | Apr 2, 2020 |
| Countries | Argentina, Australia, Belgium, Brazil, Canada, Chile, China, Germany, Greece, Hong Kong, Israel, Italy and 7 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: